Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mercaptopurine
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 15, 2024
Lead Product(s) : Mercaptopurine
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Melatonin,Mercaptopurine,Sirolimus
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Melatonin? Stem Cells? Researchers Step Up With Unconventional Approaches To COVID-19
Details : Cleveland Clinic compared COVID-19 with the coronavirus that caused the SARS outbreak of 2003 using a technique called “network proximity analysis” to identify combinations of existing drugs.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 16, 2020
Lead Product(s) : Melatonin,Mercaptopurine,Sirolimus
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mercaptopurine
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : ZonMw
Deal Size : Inapplicable
Deal Type : Inapplicable
Mercaptopurine Therapy in Ulcerative Colitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 22, 2016
Lead Product(s) : Mercaptopurine
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : ZonMw
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mercaptopurine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 02, 2012
Lead Product(s) : Mercaptopurine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mercaptopurine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 04, 2012
Lead Product(s) : Mercaptopurine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mercaptopurine
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 29, 2010
Lead Product(s) : Mercaptopurine
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable